October 9, 2023 10:55 AM EDTUpdated 11:10 AM

BridgeBio’s long-term limb-girdle muscular dystrophy data; QHP buys a CDMO

Lei Lei Wu

News Reporter

Jaimy Lee

Deputy Editor

BridgeBio shares longer-term PhII data in limb-girdle: BridgeBio said that patients with limb-girdle muscular dystrophy type 2I/R9 treated with BBP-418 saw …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BridgeBio’s long-term limb-girdle muscular dystrophy data; QHP buys a CDMO

Lei Lei Wu

News Reporter

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Bridge­Bio’s long-term limb-gir­dle mus­cu­lar dy­s­tro­phy da­ta; QHP buys a CD­MO

News Reporter

Deputy Editor

Sign up to read this article for free.

BridgeBio’s long-term limb-girdle muscular dystrophy data; QHP buys a CDMO